Since then, other CD19 CAR T-cell products, as well as the first non-CD19 directed CAR targeted to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma, have been approved [10, 13–15]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.